QIAGEN Launches Automated and AI Tools for TB Testing
QIAGEN N.V. plans to enhance its QuantiFERON latent tuberculosis testing through a new fully automated Sample to Insight workflow and an AI-enabled risk stratification tool for TB progression. These initiatives aim to support high-throughput labs, capitalizing on the increasing adoption of Diasorin LIAISON systems and a partnership with Inpeco for automation.
VENLO, Netherlands–(BUSINESS WIRE)—- $QGEN #QIAGEN–QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to advance its QuantiFERON latent tuberculosis (TB) test with a new fully automated Sample to Insight workflow and a separate AI-enabled risk stratification tool for TB progression, building on growing adoption of Diasorin LIAISON detection systems and a new automation partnership with Inpeco. These developments are intended to help higher-throughput labs scale testing as screening